SUBSCRIBERS
Lonza in joint venture to develop biotherapeutic products
Ng Ren Jye
Published Wed, Apr 3, 2019 · 09:50 PM
Singapore
SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.
The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.
Copyright SPH Media. All rights reserved.
